Governing AI in global health means protecting populations that are underrepresented in training data and often lack strong regulatory protection. This playbook covers equity and bias testing across LMIC populations, data sovereignty and the ethics of health data leaving the countries that generate it, WHO guidance on large multi-modal models and ethics, safety in offline and low-connectivity settings, and validation across the diverse populations a tool will actually serve. It gives ministries, NGOs and funders a governance model that treats fairness, sovereignty and local validation as launch gates, not afterthoughts appended after procurement.
The populations most affected are the least represented
Most clinical AI is trained on data from high-income settings. A model built on North American or European imaging can degrade sharply on different devices, different disease prevalence, and different patient populations, and the people carrying the highest disease burden are precisely those least represented in the training data. WHO addressed this directly in its 2021 guidance on ethics and governance of AI for health, and again in its 2024 guidance on large multi-modal models, warning that unrepresentative data can encode bias that widens rather than narrows health inequity. A tool that reports impressive pooled accuracy can still fail a specific subpopulation badly, and that failure is invisible unless someone deliberately tests for it across the groups the tool will actually serve.
Sovereignty compounds the risk. When a tool sends patient images or records to servers in another country for inference, the country that generated the data can lose practical control over it, including how it is stored, reused, and secured. The African Union and several national bodies have advanced data protection and localization rules, but enforcement capacity is uneven and a vendor's home-market regulation offers local patients little protection. Governance therefore cannot be outsourced to the supplier or to a distant regulator. It must be built into the engagement itself, with fairness, sovereignty, and local performance checked and documented before any consequential output is allowed to reach a clinician or a patient. The same discipline that protects patients also protects the program, because a tool later found to be biased or non-compliant can trigger a loss of trust that discredits AI across an entire health system, not just the single failed deployment.
Five governance gates before an AI tool goes live
No consequential AI output should influence care until it clears equity, sovereignty, safety, validation, and explainability gates, each with a named owner and a documented pass or fail decision recorded and auditable. Gates are not one-time hurdles; they are reviewed on a schedule, because a model that passed at launch can drift as populations, devices, and disease patterns change, and a gate that is never re-run gives false comfort rather than real assurance.
| Gate | What it checks | Evidence to pass |
|---|---|---|
| Equity and bias | Performance across sex, age, and locally relevant subpopulations | Disaggregated accuracy with no material gap between groups |
| Data sovereignty | Where data is processed, stored, and who can access it | In-country or on-device processing plus a signed data agreement |
| Offline safety | Behavior when connectivity, power, or model updates fail | Defined safe-failure mode, no silent degradation, human fallback |
| Local validation | Performance on the actual deployment population and devices | Prospective validation on local data, not transferred vendor claims |
| Explainability | Whether clinicians can see the basis for a recommendation | Source signals, confidence, and known limits surfaced to the user |
Make fairness and sovereignty enforceable
- Require disaggregated performance reporting by relevant subpopulation before approval, and reject tools that offer only a single pooled accuracy number with no breakdown.
- Insist on prospective local validation on the deployment population and hardware, treating a claim transferred from another country as a hypothesis, not evidence.
- Contract for data sovereignty explicitly: define where inference happens, prohibit unapproved secondary use, and prefer on-device or in-region processing over cross-border data transfer.
- Specify safe-failure behavior so that when connectivity or a model update fails, the tool defers to a human rather than degrading silently or presenting stale output as current.
- Adopt WHO ethics and governance guidance as the baseline, and appoint a named local clinical governance owner accountable for each deployed tool and its ongoing monitoring.
How governance fails in practice
- Accepting vendor accuracy from another market as sufficient proof the tool is safe and fair for this specific population.
- Letting patient data leave the country for inference with no enforceable data agreement, localization option, or restriction on secondary use.
- Treating bias testing as a one-time launch check rather than ongoing monitoring as populations, devices, and disease patterns shift over time.
- Deploying black-box outputs clinicians cannot interrogate, which erodes trust and hides silent failures until harm has already occurred.
Measure equity, not just accuracy
- Performance gap between the best and worst performing subpopulation, tracked continuously over time.
- Share of processing done in-country or on-device versus exported abroad for inference.
- Proportion of deployed tools with completed prospective local validation on file.
- Rate of safe human fallback events versus silent failures detected during audit.
Frequently asked questions
Why is bias a bigger risk for AI in global health?
Because the populations with the highest disease burden are the most underrepresented in training data. A model trained mostly on high-income-country data can perform well on paper yet degrade on different devices, disease prevalence, and patient groups, quietly widening health inequities. That is why WHO stresses disaggregated performance testing on the actual deployment population rather than a single pooled accuracy figure.
What does data sovereignty mean for a health AI deployment?
It means the country generating patient data keeps control over where that data is processed and stored and who can access it. In practice, prefer on-device or in-region inference, sign an enforceable data agreement, and prohibit unapproved secondary use. Do not rely on the vendor's home-country regulation to protect local patients, because it usually does not reach them.
How do you keep AI safe when connectivity drops?
Require a defined safe-failure mode. When the network, power, or a model update fails, the tool should defer to a human rather than degrade silently or present stale outputs as current. Offline safety, like bias testing and local validation, should be a governance gate the tool must pass before launch, with a named owner accountable for it.
Related reading
Go deeper on this sector and topic.